// App-Quantinova.ai

6553 : Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).

Researchers

Presenter

  • Jizu Zhi

Principal Investigators

  • Sean Khozin

  • Deborah Kuk

  • Aracelis Z. Torres

  • Rachael Sorg

  • Shannon E. Lee

  • Rebecca A. Miksad

  • Richard Pazdur

  • Amy Pickar Abernethy

Medical Centers

  • U.S. Food and Drug Administration, Silver Spring, MD

  • Flatiron Health, New York, NY

  • Duke University Medical Center, Duke Cancer Institute, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Anaplastic lymphoma Kinase

  • Epidermal growth factor receptor

  • Body mass index

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved